Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › CLDX

SILVERARC CAPITAL MANAGEMENT, LLC position in CLDX

CELLDEX THERAPEUTICS INC NEW · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 370,700 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$12.0M, representing 1.53% of its reported portfolio and ranking #20 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed CLDX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)370.70K sh
Reported value held$12.01M
Portfolio Weight1.53%
First reportedQ4 2023
Last changeNew
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's CLDX position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in CLDX in Q4 2023 at 247,215 shares (US$9.8M). The position peaked in Q2 2024 at 374,910 shares, worth US$13.9M. Across 11 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 370,700 shares valued at US$12.0M. Notable position changes include a 61% trim in Q3 2024 (shares fell 26% over the following quarter), a 82% increase in Q4 2024 (shares fell 28% over the following quarter), a 76% increase in Q3 2025 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 247.22K $9.80M New
Q1 2024 299.32K $12.56M Add
Q2 2024 374.91K $13.88M Add
Q3 2024 145.00K $4.93M Reduce
Q4 2024 264.56K $6.69M Add
Q1 2025 205.96K $3.74M Reduce
Q2 2025 198.44K $4.04M Reduce
Q3 2025 348.92K $9.03M Add
Q4 2025 191.07K $5.19M Reduce
Q1 2026 178.38K $5.66M Reduce
Q3 2026 370.70K $12.01M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CLDX and 13F data

CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 42 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$198.1M), Deep Track Capital, LP (US$109.4M), Logos Global Management LP (US$78.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CLDX

All CLDX fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held CLDX?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed CLDX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in CLDX?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 370.70K shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $12.01M, representing 1.53% of its reported portfolio and ranking #20.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling CLDX?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC newly opened its position in CLDX. The position peaked in Q2 2024 at 374.91K shares.

Which other funds hold CLDX?

Other major institutional holders of CLDX include Kynam Capital Management, LP, Deep Track Capital, LP, Logos Global Management LP, among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.